Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Nemonapride, also previously known as emonapride and sold under the brand name Emilace, is an atypical antipsychotic which is used in the treatment of schizophrenia. It is taken by mouth. Side effects of nemonapride include akathisia, dystonia, hypokinesia, tremor, hypersalivation, and hyperprolactinemia, among others. The drug acts as a dopamine D2, D3, and D4 receptor antagonist. To a lesser extent, it is also a serotonin 5-HT1A receptor partial agonist. Structurally, nemonapride is a benzamide derivative and is related to sulpiride and other benzamides. Nemonapride was introduced for medical use in either 1991 or 1997. It was developed and marketed by Yamanouchi Pharmaceuticals. The drug is approved only in Japan and China.
=== Pharmacoepidemiology and therapeutics === A 2023 study in JAMA Network Open examined changes in prescribing patterns of oral minoxidil for hair loss after media attention, using prescription data from U.S. health-system records, including those affiliated with Truveta. A 2025 study, also in JAMA Network Open, examined patterns of discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among U.S. adults with overweight or obesity using Truveta data. In 2024, a study in JAMA Internal Medicine compared the effectiveness of semaglutide versus tirzepatide for weight loss in adults with overweight or obesity, using data from Truveta-affiliated health systems.
== Hydrostatic CCC == Hydrostatic CCC or centrifugal partition chromatography (CPC) was invented in the 1980s by the Japanese company Sanki Engineering Ltd, whose president was Kanichi Nunogaki. CPC has been extensively developed in France starting from the late 1990s. In France, they initially optimized the stacked disc concept initiated by Sanki. More recently, in France and UK, non-stacked disc CPC configurations have been developed with PTFE, stainless steel or titanium rotors. These have been designed to overcome possible leakages between the stacked discs of the original concept, and to allow steam cleaning for good manufacturing practice. The volumes ranging from a 100 ml to 12 liters are available in different rotor materials. The 25-liter rotor CPC has a titanium rotor. This technique is sometimes sold under the name "fast" CPC or "high-performance" CPC.
Bacteria exhibit an extremely wide variety of metabolic types. The distribution of metabolic traits within a group of bacteria has traditionally been used to define their taxonomy, but these traits often do not correspond with modern genetic classifications. Bacterial metabolism is classified into nutritional groups on the basis of three major criteria: the source of energy, the electron donors used, and the source of carbon used for growth. Phototrophic bacteria derive energy from light using photosynthesis, while chemotrophic bacteria breaking down chemical compounds through oxidation. In both cases, metabolism can be driven by electron-transfer reactions in which electrons move from an electron donor to an electron acceptor. Chemotrophs are further divided by the types of compounds they use to transfer electrons. Bacteria that derive electrons from inorganic compounds such as hydrogen, carbon monoxide, or ammonia are called lithotrophs, while those that use organic compounds are called organotrophs. Still, more specifically, aerobic organisms use oxygen as the terminal electron acceptor, while anaerobic organisms use other compounds such as nitrate, sulfate, or carbon dioxide. Many bacteria, called heterotrophs, derive their carbon from other organic carbon. Others, such as cyanobacteria and some purple bacteria, are autotrophic, meaning they obtain cellular carbon by fixing carbon dioxide. In unusual circumstances, the gas methane can be used by methanotrophic bacteria as both a source of electrons and a substrate for carbon anabolism.
Sources: en.wikipedia.org
== Cultivation == Cut flower cultivation is intensive, usually on the basis of greenhouse monocultures, and requires large amounts of highly toxic pesticides, residues of which can often still be found in flower shops on imported flowers. As with the production of fruit and vegetables, the industry depends on significant amounts of water, which may be collected and stored by the farm owners. The Patel Dam failure in May 2018, associated with a large Kenyan rose farm, killed dozens of people. These facts have spurred the development of movements like "Slow Flowers", which propagates sustainable floriculture in the consumer country (US, Canada) itself.
=== 2000–present === In September 2002, Lilly partnered with Amylin Pharmaceuticals to develop and commercialize Amylin's new drug based on exendin-4, a novel substance isolated from the venom of the Gila monster. Exenatide, the first of the GLP-1 receptor agonists, was approved by the US Food and Drug Administration in April 2005. In 2003, Lilly introduced Cialis (tadalafil), a competitor to Viagra for erectile dysfunction developed in a partnership with Icos. Cialis maintains an active period of 36 hours, causing it sometimes to be dubbed the "weekend pill". It was advertised during the 2004 Super Bowl XXXVIII and 2005 Super Bowl XXXIX halftime shows. In 2004, Lilly introduced duloxetine (Cymbalta), a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder. It ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis. In January 2007, Lilly acquired Icos for $2.1 billion, after raising its offer and facing opposition from Institutional Shareholder Services. Lilly subsequently closed Icos' manufacturing operations, terminated nearly 500 Icos employees, leaving 127 employees working at the biologics facility. In December 2007, CMC Biopharmaceuticals A/S (CMC), a Copenhagen-based provider of contract biomanufacturing services, bought the Bothell, Washington-based biologics facility from Lilly and retained the existing 127 employees.
=== Occurrence of lactobacillic acid === Following the discovery of lactobacillic acid in the lipids of Lactobacillus arabinosus, Klaus Hofmann's team was also able to determine this fatty acid in the lipids of Lactobacillus casei with a content of 16%. It is also present in L. acidophilus, L. buchneri, L. delbrueckii subsp. bulgaricus, L. delbrueckii subsp. lactis, L. fermentum and L. helveticus with a content of 10 to 30% has been detected. However, lactobacillic acid is not restricted to members of the genus Lactobacillus or lactic acid bacteria in general. The fatty acid was also found in higher proportions (10-20%) in gram-negative bacteria, such as Agrobacterium tumefaciens and Escherichia coli detected, in smaller quantities (5-10%) also in Serratia marcescens, Klebsiella aerogenes and Pseudomonas fluorescens. Brucellaspecies also contain lactobacillic acid, as well as Bordetella species, but the content here is only 1-2%. Lactobacillic acid is found in both Gram-positive and Gram-negative bacteria and is found in strictly aerobic, microaerophilic, facultative and strictly anaerobic genera. genera. Although the fatty acid is widely distributed in bacteria, it is not found in all genera. Bacteria that do not have unsaturated fatty acids in their membrane lipids do not have lactobacillic acid. This applies in particular to thermophilic bacteria and archaea. However, the fatty acid is found rather rarely in eukaryotic organisms. It is contained, for example, in rapeseed oil, which contains little erucic acid (so-called LEAR varieties).
== Distribution == The chain catshark is found in the Northwest Atlantic, Gulf of Mexico and Caribbean, ranging from George's Bank in Massachusetts, to Nicaragua and Barbados. In the Mid-Atlantic Bight, the chain catshark is found along the outer continental shelf and upper slope. The shark occupies depths of 36 to 750 meters (118–2,461 ft); in the northern part of its range it is mainly found between 36 and 230 meters (118–755 ft) and in the southern areas generally deeper than 460 meters (1,510 ft). Due to the shark's depth distribution, it has been suggested that the shark does not perform large-scale migrations. Temperature is thought to limit the shark's distribution in northern areas, particularly during the winter. Although bands of warm water at the edge of the shelf have been observed, the temperature varies seasonally, thus limiting this non-migratory species. In general, the chain catshark is found in waters with a temperature between 8.5 °C (47 °F) and 14 °C (57 °F).
=== 2005–2013: Fading tensions === In the wake of both Fat Joe and Jadakiss being drawn into the feud, internal tensions began to affect 50 Cent's own relations within G-Unit. Despite The Game supporting G-Unit's ongoing feud with Murder Inc, his refusal to take part in separate feuds against Fat Joe or Jadakiss would quickly become a point of contention as he was later dismissed from G-Unit by 50 Cent during an on-air interview in March 2005; leading to a separate feud between both 50 Cent and The Game. Problems continued to arise for Murder Inc through 2005 as the label found itself at odds with Def Jam following their ongoing federal investigations in connection to Kenneth McGriff. The situation was made worse following a temporary acquisition by Universal Music in which Irv Gotti found himself unable to secure any further funding for the label shortly thereafter. Existing tensions between 50 Cent and Fat Joe boiled over during the 2005 MTV Video Music Awards when Fat Joe presented the award for best Hip Hop Video, in which he told the audience "I feel so safe tonight with all this police protection courtesy of G-Unit". 50 Cent later retaliated with a profanity-laden diatribe following his performance of the song "So Seductive" with fellow G-Unit artist Tony Yayo, exclaiming "Fat Joe's a pussy man! [...] Pussy Boy, Nigga What?!".
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.